Clinical Trial Update: Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol [Phase 1]

View source ↗

Summary

Phase 1 study assessing pharmacokinetics and safety of beclomethasone dipropionate HFA nasal aerosol in allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• BDP HFA Nasal Aerosol (beclomethasone dipropionate nasal aerosol)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Allergic Rhinitis | Phase 1 | Status: COMPLETED